marijuana stocks news

Vaporin, Inc. (VAPO)

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013
Total Revenue 837   419   183   (28)
Cost of Revenue 424 238 115
Gross Profit 413   181   67   13  
Operating Expenses
Research Development
Selling General and Administrative 1,792 1,659 821 2,975
Non Recurring
Others 7 3 3
Total Operating Expenses
Operating Income or Loss (1,386) (1,481) (757) (2,963)
Income from Continuing Operations
Total Other Income/Expenses Net 81 135 (130) 581
Earnings Before Interest And Taxes (1,305) (1,346) (887) (2,382)
Interest Expense 53 94 251 102
Income Before Tax (1,358) (1,440) (1,138) (2,484)
Income Tax Expense
Minority Interest
Net Income From Continuing Ops (1,358) (1,440) (1,138) (2,484)
Non-recurring Events
Discontinued Operations (537)
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (1,358) (1,440) (1,138) (3,021)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (1,358) (1,440) (1,138) (3,021)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Trulieve Cannabis Corp. (TCNNF) to Hold Third Quarter 2021 Earnings Conference Call on November 15, 2021

Trulieve Cannabis Corp. to Hold Third Quarter 2021 Earnings Conference Call on…

mCig, Inc. (MCIG) to Spin-Off Technology Division as a Stand-Alone Public Company

mCig to Spin-Off Technology Division as a Stand-Alone Public Company mCig, Inc. ( OTCQB : MCIG ),…

 Lifestyle Delivery Systems Inc. (LDSYF) Announces the Adelanto City Council’s Approval to Include Cannabis Adult Use into the City Regulations

Lifestyle Delivery Systems Inc. Announces the Adelanto City Council’s Approval to Include…

INSYS Therapeutics, Inc. (INSY) Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution

INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution…